Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.640
-0.090 (-3.30%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Protalix BioTherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 80.62 | 52.74 | 53.4 | 65.49 | 47.64 | 38.35 | |
Revenue Growth | 30.14% | -1.23% | -18.47% | 37.48% | 24.22% | -39.03% |
Cost of Revenue | 43.72 | 45.88 | 36.7 | 39.3 | 48.42 | 16.35 |
Gross Profit | 36.9 | 6.86 | 16.7 | 26.2 | -0.79 | 22 |
Selling, General & Admin | 12.62 | 11.68 | 12.19 | 14.96 | 11.71 | 12.73 |
Research & Development | 0.99 | 0.68 | 0.59 | 0.78 | 0.52 | 29.73 |
Operating Expenses | 13.61 | 12.36 | 12.78 | 15.74 | 12.23 | 42.46 |
Operating Income | 23.29 | -5.5 | 3.92 | 10.46 | -13.01 | -20.46 |
Interest Expense | -1.23 | -1.19 | -1.06 | -3.18 | -2.53 | -7.52 |
Interest & Investment Income | 1.4 | 1.08 | 1.3 | 1.29 | 1.15 | 0.4 |
EBT Excluding Unusual Items | 23.46 | -5.61 | 4.15 | 8.57 | -14.4 | -27.58 |
Pretax Income | 23.46 | -5.61 | 4.15 | 8.57 | -14.4 | -27.58 |
Income Tax Expense | 4.52 | 1 | 1.22 | 0.25 | 0.53 | - |
Earnings From Continuing Operations | 18.95 | -6.6 | 2.93 | 8.31 | -14.93 | -27.58 |
Net Income | 18.95 | -6.6 | 2.93 | 8.31 | -14.93 | -27.58 |
Net Income to Common | 18.95 | -6.6 | 2.93 | 8.31 | -14.93 | -27.58 |
Net Income Growth | 201.91% | - | -64.73% | - | - | - |
Shares Outstanding (Basic) | 80 | 79 | 73 | 68 | 48 | 44 |
Shares Outstanding (Diluted) | 81 | 79 | 81 | 82 | 48 | 44 |
Shares Change | -2.61% | -3.10% | -1.66% | 70.04% | 9.81% | 51.43% |
EPS (Basic) | 0.24 | -0.08 | 0.04 | 0.12 | -0.31 | -0.62 |
EPS (Diluted) | 0.24 | -0.08 | 0.04 | 0.09 | -0.31 | -0.62 |
EPS Growth | 205.32% | - | -57.71% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 7.67 | -13.63 | 7.39 | -2.47 | -25.63 | -11.74 |
Free Cash Flow Per Share | 0.10 | -0.17 | 0.09 | -0.03 | -0.53 | -0.27 |
Gross Margin | 45.77% | 13.01% | 31.27% | 40.00% | -1.65% | 57.37% |
Operating Margin | 28.89% | -10.43% | 7.33% | 15.97% | -27.32% | -53.36% |
Profit Margin | 23.50% | -12.52% | 5.49% | 12.69% | -31.33% | -71.92% |
Free Cash Flow Margin | 9.51% | -25.84% | 13.84% | -3.77% | -53.80% | -30.62% |
EBITDA | 24.86 | -4.04 | 5.22 | 11.65 | -11.93 | -19.34 |
EBITDA Margin | 30.84% | -7.65% | 9.78% | 17.79% | -25.04% | -50.44% |
D&A For EBITDA | 1.57 | 1.47 | 1.3 | 1.19 | 1.09 | 1.12 |
EBIT | 23.29 | -5.5 | 3.92 | 10.46 | -13.01 | -20.46 |
EBIT Margin | 28.89% | -10.43% | 7.33% | 15.97% | -27.32% | -53.36% |
Effective Tax Rate | 19.26% | - | 29.42% | 2.96% | - | - |
Revenue as Reported | 80.62 | 52.74 | 53.4 | 65.49 | 47.64 | 38.35 |